Patterns Of Total Cost For Patients (Pts) With Active Treatment (Tx) Of Myelodysplastic Syndromes (Mds).

e18252Background: Lenalidomide (LEN) and azacitidine (AZA) are 2 standard active Tx options recommended by national guidelines for pts with MDS. Limited information exists on the total cost of care for pts treated with these agents. This descriptive analysis evaluated real-world costs for US pts without higher-risk MDS at diagnosis. Methods: Pts were identified from the MarketScan US claims database (2008–2013) by ICD-9 codes. Initial MDS diagnosis defined the index date. Pts with ≥ 12 months pre- and ≥ 6 months post-index enrollment were included; pts with codes for high-grade MDS or acute myeloid leukemia at diagnosis, or concomitant LEN + AZA use, were excluded. Pt cohorts based on first active Tx post-index were followed up to the earliest of: end of data, 24 months, or Tx change. A generalized linear model was used to control for baseline differences between groups. Results: 1,402 pts met the inclusion criteria (LEN, n = 456; AZA, n = 946). At baseline, 48% and 52%, respectively, were aged ≥ 75 years...